drugset / Trial / NCT03778593
FOLFIRINOX for 2nd-line Treatment of BTC
NaSingle-groupOpen-labelTreatment
Summary
Biliary tract cancer (BTC) is rare in the West, but it is relatively high in Asia, including Korea. Currently used as the standard primary treatment in metastatic or locally advanced BTC is gemcitabine/platinum combination chemotherapy.There is no standard secondary chemotherapy recognized after the failure of the gemcitabine/platinum first line treatment. The investigators try to evaluate role of 5-FU, leucovorin, irinotecan, and oxaliplatin combination chemotherapy (FOLFIRINOX) for the patients who progressed after gemcitabine/cisplatin first line chemotherapy.
Timeline
- Start
- 2019-03-01
- Primary completion
- 2019-03-01
- Completion
- 2021-01-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 135 mg/m2 | Intravenous |
| Subject | Leucovorin | Small molecule | 400 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 65 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 1000 mg/m2 | Intravenous |